Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 27, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event
September 12, 2022 07:00 ET
|
Dyne Therapeutics, Inc.
- Presentation and Discussion with Two Leading Neuromuscular Disease Experts - - Data from DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Anticipated in the Second Half of 2023 - - Refined...
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 06, 2022 07:01 ET
|
Dyne Therapeutics, Inc.
- First Patient Expected to be Dosed in September - - Data from Global, Multiple Ascending Dose ACHIEVE Trial Anticipated in the Second Half of 2023 - - Dyne to Host “Spotlight on the Clinic”...
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
September 06, 2022 07:00 ET
|
Dyne Therapeutics, Inc.
- Data from Global, Multiple Ascending Dose DELIVER Trial Anticipated in the Second Half of 2023 - - Dyne to Host “Spotlight on the Clinic” Virtual Event on September 12 - WALTHAM, Mass., Sept. ...
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development
August 29, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- Appointment Expands Dyne’s Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:...
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
August 10, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc....
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 04, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Dyne...
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
July 12, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 - - Executing on Global Clinical and Regulatory Strategy: Clinical Trial...
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
July 05, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 - WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) --...